| Literature DB >> 36187731 |
Li Liu1,2, Mingjuan Yuan3, Siqing Sun4, Jinrong Wang5, Yi Shi6, Yamin Yu7, Xin Su1,6.
Abstract
Background: For acquired immunodeficiency syndrome (AIDS) patients with suspected opportunistic infections, the rapid and accurate identification of pathogens remains a challenge. Metagenomic next-generation sequencing (mNGS) has emerged as a pan-pathogen assay for infectious diseases diagnosis, but its guiding significance for diagnosis and antimicrobials treatment in AIDS patients with suspected opportunistic infections is still not well established. In this study, we compared the microbiological diagnostic value of mNGS with that of conventional microbiological tests (CMTs) in AIDS patients with suspected opportunistic infections.Entities:
Keywords: AIDS; mNGS; opportunistic infections
Year: 2022 PMID: 36187731 PMCID: PMC9518679 DOI: 10.2147/IDR.S378249
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.177
The Detailed Information Related to 86 Patients of AIDS Patients with Suspected Opportunistic Infections
| n=86 | |||||
|---|---|---|---|---|---|
| Age, Years (Range) | Female/Male | Pneumonia | Blood Stream Infection | Central Nervous System Infection | |
| Hunan Provincial People’s Hospital | 45.75 (28–55) | 0/4 | 2 | 0 | 2 |
| The Central Hospital of Yueyang | 41.5 (27–71) | 6/28 | 16 | 12 | 6 |
| Second Hospital of Nanjing | 43.5 (32–77) | 11/35 | 37 | 6 | 3 |
| Hengshui People’s Hospital | 36.5 (28–45) | 0/2 | 1 | 0 | 1 |
Figure 1The proportion of samples in this study.
Clinical Characteristics of AIDS Patients with Suspected Opportunistic Infections
| n = 86 | |
|---|---|
| Demographics | |
| 42.8 (range: 27–77) | |
| 17/69 | |
| Increased WBC (×109 /L) | 18/86 (20.9%) |
| Increased CRP (mg/L) | 26/86 (30.2%) |
| Increased PCT (ng/mL) | 21/86 (24.4%) |
| Median CD4 count, cells/mm3 | 56.9 cells/mm3 |
| Anti-retroviral therapy | 54/86 (62.8%) |
Abbreviations: WBC, white blood cells; CRP, C-reactive protein; PCT, procalcitonin.
Figure 2Breakdown of organisms identified by both metagenomics next-generation sequencing (mNGS) and conventional microbiological tests (CMTs), mNGS only, and CMTs only.
Pathogens Missed by mNGS
| Microbe | Count | Culture | Smear | Serology | Cilnical Diagnosis |
|---|---|---|---|---|---|
| Nontuberculosis mycobacteria | 5 | 2 | 3 | ||
| Mycobacterium tuberculosis | 4 | 1 | 1 | 2 | |
| Syphilis | 4 | 4 | |||
| Toxoplasma Gondii | 1 | 1 |
Comparison of the Use Proportion of Antimicrobials Between Pre-mNGS and After-mNGS in Patients
| Antimicrobials | Pre-mNGS | After-mNGS | P value |
|---|---|---|---|
| Moxifloxacin | 30/86(34.9%) | 9/86 (10.5%) | 0.0001 |
| Meropenem | 8/86 (9.3%) | 3/86 (3.5%) | 00.119 |
| Piperacillin Sodium and Tazobactam Sodium | 20/86 (23.3%) | 16/86 (11.6%) | 00.453 |
| Foscarnet | 45/86 (52.3%) | 20/86 (23.26%) | <0.0001 |
| Cefoperazone Sodium and Sulbactam Sodium | 18/86(20.9%) | 9/86(10.5%) | 00.059 |
| Levofloxacin | 28/86 (32.6%) | 12/86 (14%) | 00.003 |
| Imipenem-Cilastatin sodium hydrate | 12/86 (14%) | 7/86 (8.1%) | 00.223 |
| Fluconazole | 6/86 (7%) | 3/86 (3.5%) | 00.304 |
| Itraconazole | 5/86 (5.8%) | 5/86(5.8%) | 1 |
| Voriconazole | 6/86 (7%) | 6/86(7%) | 1 |
| Amphotericin B | 8/86 (9.3%) | 16/86 (18.6%) | 00.078 |
| Caspofungin | 10/86 (11.6%) | 20/86(31.4and) | 00.001 |
| Acyclovir | 6/86 (7%) | 14/86 (16.3%) | 0.057 |